Royal London Asset Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $79.3M | Buy |
2,823,465
+24,566
| +0.9% | +$654K | 0.17% | 127 |
|
|
2025
Q4 | $69.7M | Sell |
2,798,899
-21,161
| -0.8% | -$534K | 0.15% | 135 |
|
|
2025
Q3 | $71.9M | Buy |
2,820,060
+179,928
| +7% | +$4.44M | 0.15% | 129 |
|
|
2025
Q2 | $64M | Sell |
2,640,132
-46,966
| -2% | -$1.1M | 0.15% | 136 |
|
|
2025
Q1 | $68.1M | Buy |
2,687,098
+226,022
| +9% | +$5.91M | 0.16% | 118 |
|
|
2024
Q4 | $65.3M | Buy |
2,461,076
+67,788
| +3% | +$1.84M | 0.16% | 113 |
|
|
2024
Q3 | $69.3M | Buy |
2,393,288
+63,687
| +3% | +$1.86M | 0.17% | 110 |
|
|
2024
Q2 | $65.2M | Sell |
2,329,601
-18,878
| -0.8% | -$520K | 0.17% | 108 |
|
|
2024
Q1 | $65.2M | Sell |
2,348,479
-3,067
| -0.1% | -$85.1K | 0.16% | 116 |
|
|
2023
Q4 | $67.7M | Buy |
2,351,546
+38,236
| +2% | +$1.16M | 0.19% | 99 |
|
|
2023
Q3 | $76.7M | Buy |
2,313,310
+113,175
| +5% | +$4M | 0.25% | 82 |
|
|
2023
Q2 | $80.7M | Buy |
2,200,135
+185,592
| +9% | +$7.22M | 0.26% | 71 |
|
|
2023
Q1 | $82.2M | Buy |
2,014,543
+20,804
| +1% | +$899K | 0.33% | 60 |
|
|
2022
Q4 | $102M | Buy |
1,993,739
+76,235
| +4% | +$3.65M | 0.46% | 44 |
|
|
2022
Q3 | $84.1M | Sell |
1,917,504
-65,790
| -3% | -$3.2M | 0.43% | 47 |
|
|
2022
Q2 | $104M | Buy |
1,983,294
+14,931
| +0.8% | +$761K | 0.48% | 44 |
|
|
2022
Q1 | $102M | Buy |
1,968,363
+75,957
| +4% | +$3.94M | 0.4% | 52 |
|
|
2021
Q4 | $112M | Sell |
1,892,406
-69,889
| -4% | -$3.46M | 0.42% | 51 |
|
|
2021
Q3 | $84.4M | Sell |
1,962,295
-51,677
| -3% | -$2.29M | 0.34% | 58 |
|
|
2021
Q2 | $78.9M | Sell |
2,013,972
-42,143
| -2% | -$1.64M | 0.32% | 63 |
|
|
2021
Q1 | $74.5M | Buy |
2,056,115
+25,711
| +1% | +$913K | 0.34% | 65 |
|
|
2020
Q4 | $74.7M | Sell |
2,030,404
-202,645
| -9% | -$7.43M | 0.39% | 59 |
|
|
2020
Q3 | $76.6M | Sell |
2,233,049
-7,964
| -0.4% | -$279K | 0.46% | 48 |
|
|
2020
Q2 | $69.4M | Sell |
2,241,013
-70,320
| -3% | -$2.39M | 0.48% | 42 |
|
|
2020
Q1 | $71.7M | Sell |
2,311,333
-19,534
| -0.8% | -$666K | 0.58% | 31 |
|
|
2019
Q4 | $86.1M | Buy |
2,330,867
+40,858
| +2% | +$1.46M | 0.6% | 33 |
|
|
2019
Q3 | $78.1M | Sell |
2,290,009
-65,763
| -3% | -$2.39M | 0.59% | 33 |
|
|
2019
Q2 | $96.9M | Sell |
2,355,772
-90,131
| -4% | -$3.58M | 0.92% | 16 |
|
|
2019
Q1 | $98.6M | Sell |
2,445,903
-178,599
| -7% | -$7.15M | 0.78% | 20 |
|
|
2018
Q4 | $107M | Buy |
2,624,502
+176,900
| +7% | +$7.34M | 0.94% | 15 |
|
|
2018
Q3 | $102M | Sell |
2,447,602
-141,249
| -5% | -$5.44M | 1.05% | 15 |
|
|
2018
Q2 | $89.1M | Buy |
+2,588,851
| New | +$88.5M | 0.9% | 19 |
|
|
2016
Q2 | $72.7M | Sell |
2,175,070
-43,650,768
| -95% | -$1.39B | 1.19% | 14 |
|
|
2016
Q1 | $1.47M | Buy |
45,825,838
+43,554,416
| +1,917% | +$1.24B | 2.1% | 5 |
|
|
2015
Q4 | $70.5M | Sell |
2,271,422
-17,359
| -0.8% | -$546K | 1.09% | 13 |
|
|
2015
Q3 | $68.2M | Buy |
+2,288,781
| New | +$73.4M | 1.1% | 14 |
|
|
2014
Q4 | $629K | Buy |
2,113,365
+463,403
| +28% | +$13.3M | 1.19% | 12 |
|
|
2014
Q3 | $46.6M | Buy |
1,649,962
+83,551
| +5% | +$2.34M | 1.17% | 15 |
|
|
2014
Q2 | $42M | Sell |
1,566,411
-6,796
| -0.4% | -$194K | 0.97% | 18 |
|
|
2014
Q1 | $43.5M | Sell |
1,573,207
-68,675
| -4% | -$2.05M | 1.01% | 15 |
|
|
2013
Q4 | $47.8M | Sell |
1,641,882
-18,781
| -1% | -$547K | 1.21% | 12 |
|
|
2013
Q3 | $48.2M | Sell |
1,660,663
-110,445
| -6% | -$3.01M | 1.29% | 10 |
|
|
2013
Q2 | $47.4M | Buy |
+1,771,108
| New | +$48.9M | 1.38% | 11 |
|
Other funds holding PFE
VCM
VPM
Royal London Asset Management's PFE Position: Q1 2026 in Review
Royal London Asset Management increased its Pfizer (PFE) stake by 0.88% in Q1 2026, buying an estimated $654K and bringing the position to 2,823,465 shares worth $79.3M. The position accounts for 0.17% of the portfolio, ranked #127.
Royal London Asset Management first reported a position in PFE in Q2 2013 and has held it in 43 quarters since. The position peaked at $112M in Q4 2021. 2,938 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Royal London Asset Management held 2,823,465 shares of Pfizer worth $79.3M as of Q1 2026.
- Royal London Asset Management bought 24,566 Pfizer shares in Q1 2026, an estimated $654K.
- Pfizer made up 0.17% of Royal London Asset Management's portfolio in Q1 2026, its #127 holding.
- Royal London Asset Management first reported a position in Pfizer in Q2 2013 and has held it in 43 quarters since.
- Royal London Asset Management's Pfizer position peaked at $112M in Q4 2021.
- 2,938 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Royal London Asset Management's 13F filing for Q1 2026, filed 1 May 2026.